Skip to content


The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

Not all products are cleared or available for sale in all Asia Pacific countries.

By clicking on the button "Accepted and Confirmed" you assure that you have taken note of this information and that you are a healthcare professional.

sleep•safe harmony

Because patients are different

Your patients have a chronic kidney disease in common, but they differ in many ways: age, height, weight, stage of illness, residual renal function etc. These differences have a decisive impact on the required PD treatment:

Important parameters for successful PD:

  • Age
  • Weight
  • D/P creatinine
  • Residual renal function (RFF)
  • Ultrafiltration (UF)
  • Ut/V urea

Adapted APD (aAPD) therapy - Different patients, different settings

Adapted APD (aAPD) therapy with sleep•safe harmony enables you to combine sequences of short dwells and small fill volumes with long dwells and large fill volumes and varying glucose concentrations. aAPD is a new way of prescribing PD that optimises ultrafiltration (UF) and clearance within one PD session.


A clinical study comparing aAPD to conventional APD showed 1,2 :

  • Increased ultrafiltration
  • Optimised clearances
  • Better peritoneal sodium and phosphate removal
  • Reduction of mean blood pressure

sleep•safe harmony enables:

  • Complete individualisation for a fully personalised treatment
  • Guided prescription on the cycler or via PatientOnLine software

Patient A - Anu

At the start of aAPD the patient (fast transporter) had residual renal function (urine) of 1500 ml and good solute clearance. Prescription was 5 X APD therapy. Treatment continued for 2 years.

Due to disease progression, UF decreased and urine declined to 400 ml.

She was started on aAPD, with 1.5% glucose solution and short term 2.3% to alleviate fluid overload.

Anu Before aAPD therapy After aAPD therapy


58 kg

58 kg





3.2 mL/min

3.2 mL/min


500 mL

650 mL




Patient B - Jack

Patient is diabetic (slow transporter) and started receiving APD for about 2 years. At least once a week in HD, because he was fluid overloaded. RRF also started to decrease gradually.

aAPD with same amount of fluid volume and time as before was started. 2 cycles of 1500 ml with 4.25% glucose solution in the beginning to remove access water and treatment continued with 1.5% glucose.

Jack Before aAPD therapy After aAPD therapy


79 kg

79 kg





600 mL/min

650 mL/min


700 mL

1100 mL




Key features of the sleep•safe harmony cycler

sleep•safe harmony offers advanced features aimed at improving patient care. It also contributes to the improvement of patient compliance and saves training time.

Key features overview

FlexPoint intelligence

  • Any therapy with sleep•safe harmony is supported by FlexPoint technology

  • Permitted patient volume - which is the maximum individual fill volume

  • Permitted residual volume - which is the maximum volume, which may remain in the patient's peritoneal cavity

The goal

  • Achieve optimised treatment efficiency
  • Keep the prescribed treatment time
  • Minimize potential alarms
  • Avoid overfilling for patient’s well-being and security
Other features

Training support:

  • Guiding animations directly on the device

  • Large touch screen

Guided prescriptions:

  • Create prescriptions directly on the device

  • On screen keyboard

  • Optimised fluid usage - no extra volume for priming

Convenient handling:

  • Automatic connection and barcode recognition of bags

  • Integrated handles

  • PatientCardPlus with more than 12 months capacity of treatment data

Simple installation:

  • Plug & use – no transformer needed due to double insulation

1 Fischbach M, Issad B, Dubois V, Taamma R. The beneficial influence on the effectiveness of automated peritoneal dialysis of varying the dwell time (short/long) and fill volume (small/large): randomized controlled trial. Perit Dial Int 2011; 31(4):450-8

2 Fischbach M et al, Abstract poster presentation at ASN 2010 in Denver, US